Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175619
Title: | Blood test dynamics in hospitalized COVID-19 patients: Potential utility of D-dimer for pulmonary embolism diagnosis |
Author: | Cerdà, Pau Ribas, Jesús Iriarte, Adriana Mora Luján, José María Torres, Raquel Río, Belén del Jofré, Héctor Ignacio Ruiz, Yolanda Huguet, Marta Fuset, Maria Paz Martínez Yélamos, Sergio Santos, Salud Llecha, Núria Corbella, Xavier Riera Mestre, Antoni |
Keywords: | COVID-19 Embòlia pulmonar Anticoagulants (Medicina) Tromboembolisme COVID-19 Pulmonary embolism Anticoagulants (Medicine) Thromboembolism |
Issue Date: | 28-Dec-2020 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Background: A higher incidence of thrombotic events, mainly pulmonary embolism (PE), has been reported in hospitalized patients with COVID-19. The main objective was to assess clinical and laboratory differences in hospitalized COVID-19 patients according to occurrence of PE. Methods: This retrospective study included all consecutive patients hospitalized with COVID-19 who underwent a computed tomography (CT) angiography for PE clinical suspicion. Clinical data and median blood test results distributed into weekly periods from COVID-19 symptoms onset, were compared between PE and non-PE patients. Results: Ninety-two patients were included, 29 (32%) had PE. PE patients were younger (63.9 (SD 13.7) vs 69.9 (SD 12.5) years). Clinical symptoms and COVID-19 CT features were similar in both groups. PE was diagnosed after a mean of 20.0 (SD 8.6) days from the onset of COVID-19 symptoms. Corticosteroid boluses were more frequently used in PE patients (62% vs. 43%). No patients met ISTH DIC criteria. Any parameter was statistically significant or clinically relevant except for D-Dimer when comparing both groups. Median values [IQR] of D-dimer in PE vs non-PE patients were: week 2 (2010.7 [770.1-11208.9] vs 626.0 [374.0-2382.2]; p = 0.004); week 3 (3893.1 [1388.2-6694.0] vs 1184.4 [461.8-2447.8]; p = 0.003); and week 4 (2736.3 [1202.1-8514.1] vs 1129.1 [542.5-2834.6]; p = 0.01). Median fold-increase of D-dimer between week 1 and 2 differed between groups (6.64 [3.02-23.05] vs 1.57 [0.64-2.71], p = 0.003); ROC curve AUC was 0.879 (p = 0.003) with a sensitivity and specificity for PE of 86% and 80%, respectively. Conclusions: Among hospitalized COVID-19 patients, D-dimer levels are higher at weeks 2, 3 and 4 after COVID-19 symptom onset in patients who develop PE. This difference is more pronounced when the fold increase between weeks 1 and 2 is compared. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0243533 |
It is part of: | PLoS One, 2020, vol. 15, num. 12, p. e0243533 |
URI: | http://hdl.handle.net/2445/175619 |
Related resource: | https://doi.org/10.1371/journal.pone.0243533 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
708410.pdf | 1.3 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License